: ./template/pc/banner.htm
  1. 首页 > Forum Structure
Main Forum

  • Interpretation of the Latest Version of Drug Registration Regulation

  • Current Biopharma Industry Development Trends Under the Pandemic Threaten

  • Seize the Opportunity to Internationally Compatible – Current MAH System

  • Biosimilar and Innovative Drugs Are on the Market in International Competition under ICH 

  • Challenges and Opportunities in R & D of Global Biopharma: New Era, New Opportunity and New Direction

  • How to Respond to the Similar "Black Swan" Incident After Pandemic? During the Outbreak of Covid-19, How to Shorten the R&D Cycle and Accelerate Vaccine into Market?




Sub-Forum I：
Biopharmaceutical Process and Manufacture

  • Development of Biopharmaceutical Manufacturing Processes and Development

  • Biopharmaceutical Process Development in Compliance with ICH Guidelines and Non-Clinical Drug Study Quality Management Specification (GLP) Standards

  • CMC Quality Assessment and Approval of Continuous Manufacturing of Biological Products

  • Case Study: Integrated Solutions Platform and Case Study for Continuous Biopharmaceutical Production




Sub-Forum II：
Biopharmaceutical Registration Approval & Application

  • Latest Trends in Biopharmaceutical Regulation Worldwide

  • Selection and Management Strategy of Biopharmaceutical CDMO Under MAH Policy

  • Multi-Center Clinical Development Strategy and Trial Design of Biopharmaceuticals Under Global Application

  • IND for Clinical Trial and IND for New Drug in Biological Innovative Drug Development




Sub-Forum III：
Biosimilar Technology Frontiers

  • Comparison and Interpretation of Biosimilar approved by FDA, EMA, NMPA

  • Biosimilar Development of Clinical Similarity

  • How to speed up the Process of Clinical Trials of Biosimilar to Shorten Time to Market?

  • Patent Strategy during R&D of Biosimilar Products




Sub-Forum Ⅳ：
Gene Therapy and Immunotherapy Innovation

  • Research and Exploration of CAR-T Cell Therapy in Solid Tumors

  • Designs and Development of Universal CAR-T Cells

  • PD-1 Monoclonal Antibody’s (mAb’s) Clinical Process of New Indications

  • Discovery, Designs and Development Strategies for Innovative Immunotherapy Antibody, ADC and Bispecific Antibodies (BsAbs)

  • Oncolytic Virus Preparation and Industrialization Prospects

  • Global Consensus on Cooperative R&D of Immunotherapy